Market Research Logo

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016’, provides in depth analysis on Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted pipeline therapeutics.

The report provides comprehensive information on the Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105)
  • The report reviews Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) Overview
Therapeutics Development
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Stage of Development
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Therapy Area
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Indication
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Companies
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Companies Involved in Therapeutics Development
Chrysalis Pharma SAS
Griffin Discoveries BV
Johnson & Johnson
OSE Pharma SA
Palau Pharma, S.A.
Sensorion S.A.
Ziarco Pharma Ltd
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Drug Profiles
GD-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-48 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-28307474 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-28610244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-40279486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SENS-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toreforant tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tritoqualine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UR-63325 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPL-3893787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Dormant Projects
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Discontinued Products
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Featured News & Press Releases
Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting
Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389
Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218
Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo
Jun 18, 2014: Ziarco Secures £1.7M Grant from UK’s Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis
Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Chrysalis Pharma SAS, H1 2016
Pipeline by Griffin Discoveries BV, H1 2016
Pipeline by Johnson & Johnson, H1 2016
Pipeline by OSE Pharma SA, H1 2016
Pipeline by Palau Pharma, S.A., H1 2016
Pipeline by Sensorion S.A., H1 2016
Pipeline by Ziarco Pharma Ltd, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report